Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers

Analysis of 4,405 variants in 89,050 European subjects from 41 case-control studies identified three independent association signals for estrogen-receptor-positive tumors at 11q13. The strongest signal maps to a transcriptional enhancer element in which the G allele of the best candidate causative variant rs554219 increases risk of breast cancer, reduces both binding of ELK4 transcription factor and luciferase activity in reporter assays, and may be associated with low cyclin D1 protein levels in tumors. Another candidate variant, rs78540526, lies in the same enhancer element. Risk association signal 2, rs75915166, creates a GATA3 binding site within a silencer element. Chromatin conformation studies demonstrate that these enhancer and silencer elements interact with each other and with their likely target gene, CCND1.

On-Line Emission Analysis of Polycyclic Aromatic Hydrocarbons down to pptv Concentration Levels in the Flue Gas of an Incineration Pilot Plant with a Mobile Resonance-Enhanced Multiphoton Ionization Time-of-Flight Mass Spectrometer

A newly developed, mobile laser mass spectrometer (resonance-enhanced multiphoton ionization - time-of-flight mass spectrometer, REMPI-TOFMS) was applied to on-line measurements at a waste incineration pilot plant. REMPI-TOFMS combines the optical selectivity of resonance-enhanced multiphoton ionization with a time-of-flight mass analysis to give a two-dimensional analytical method. Special care was taken to build up a sampling and inlet system suitable for on-line measurements of large, semivolatile polycyclic aromatic hydrocarbons (PAHs). An effusive molecular beam inlet in combination with a fixed frequency UV laser (Nd:YAG at 266 nm or KrF excimer at 248 nm) was used. Under these conditions, many different PAHs can be ionized selectively from the complex flue gas matrix. For example, the achieved detection limit for naphthalene is in the 10 parts-per-trillion by volume (pptv) concentration range. Calibration was performed by using external concentration standards supplied in low ppbv concentrations. The instrumentation is sufficiently robust to be operated under industrial conditions at incineration plants, for instance. The REMPI mass spectra can be acquired at 5-50 Hz. Time profiles of the concentrations of different PAHs in the flue gas were monitored with a time resolution of 200 ms. Significant variations in the concentration profile of several PAHs up to mass 276 amu (e.g., benzo[ghi]perylene) and methylated PAHs have been observed while combustion parameters were changing. In summary, it was demonstrated that laser mass spectrometry (REMPI-TOFMS) enables a real-time on-line trace analysis of combustion flue gases or industrial process gases.

Proteases associated with gynecological tumors

Proteases are involved in the invasion and metastasis of tumours by destruction of the basal membrane and connective tissue. As levels in malignant tissue have both prognostic and therapeutic implications, we examined 318 frozen samples from malignant tumours and comparable non-malignant tissue looking for urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels with ELISA, as well as cathepsin D with RIA. Oestrogen receptor (ER) levels, progesterone receptor (PrgR) levels and epidermal growth factor receptors (EGFR) were measured by biochemical methods at the same time. Significantly raised levels of uPA, PAI-1 and cathepsin D were found in malignant tissue, with PAI-1 particularly high in carcinoma of the cervix. Significantly raised tPA levels were found in breast cancer tissue with a more favourable clinical prognosis, with a positive correlation between tPA and ER. No correlation could be shown between uPA, PAI-1 and cathepsin D with other prognostic factors for breast cancer. It could be that routine, uncomplicated estimation of tumour-associated proteases such as uPA, tPA, PAI-1 and cathepsin D will provide an independent prognostic marker for therapeutic decisions with regard to gynaecological tumours and breast cancer.

Biochemical and immunohistochemical detection of the epidermal growth-factor receptor (EGF-R) in breast-tumor specimens

Analyses of the level of expression of the epidermal growth factor receptor (EGF-R) of breast cancer tumors may add independent information about the prognosis of individual patients. Furthermore, the use of monoclonal antibodies directed against EGF-R as therapeutic tools (e.g., Mab 425) requires a reliable evaluation of the individual EGF-R content. Various analytical methods have been published, including (Scarff RW and Torloni H: World Health Organization, Geneva, 1968), biochemical detection of EGF-R by a radiolabeled physiologic ligand [I-125]EGF, (Early Breast Cancer Trialists' Collaborative Group: Lancet 329: 1-15, 1992) biochemical analyses of EGF-R content with a monoclonal antibody, and (McGuire WL and Clark GM: N Engl J Med 326: 1756-1761, 1992) immunohistochemical EGF-R detection. We measured the EGF-R content in membrane pellets derived from routine processing for evaluation of estrogen (ER, ER-EIA) and progesterone receptor (PgR; PgR-EIA) in 185 breast cancers and 18 benign breast samples, using a single-point saturation assay (RBA). Simultaneously, ER (ER-ICA), PgR (PgR-ICA), and EGF-R immunohistochemistry was performed on frozen sections of the same tumors. Various cell lines and normal skin tissue samples served as EGF-R positive or negative controls. The results of the two different EGF-R analyzing methods were compared with other biological characteristics of the tumors. 37% of the tumors were EGF-R positive. There was an inverse correlation between the ER or PgR and the EGF-R content. EGF-R overexpression correlated with high tumor grade. Analyses of EGF-R content in membrane pellets of breast cancer samples by single point saturation assay as well as the evaluation of tumor sections by immunohistochemistry can be performed routinely. The results obtained with both analytical methods did not differ significantly. but the immunohistochemistry proved to be more difficult to perform and to interpret. Thus, we prefer to perform both analytical methods simultaneously to provide information potentially useful for clinical management of individual cancer patients.